Normal Cells, but Not Cancer Cells, Survive Severe Plk1 Depletion
Overview
Authors
Affiliations
We previously reported the phenotype of depletion of polo-like kinase 1 (Plk1) using RNA interference (RNAi) and showed that p53 is stabilized in Plk1-depleted cancer cells. In this study, we further analyzed the Plk1 depletion-induced phenotype in both cancer cells and primary cells. The vector-based RNAi approach was used to evaluate the role of the p53 pathway in Plk1 depletion-induced apoptosis in cancer cells with different p53 backgrounds. Although DNA damage and cell death can occur independently of p53, p53-deficient cancer cells were much more sensitive to Plk1 depletion than cancer cells with functional p53. Next, the lentivirus-based RNAi approach was used to generate a series of Plk1 hypomorphs. In HeLa cells, two weak hypomorphs showed only slight G2/M arrest, a medium hypomorph arrested with 4N DNA content, followed later by apoptosis, and a strong Plk1 hypomorph underwent serious mitotic catastrophe. In well-synchronized HeLa cells, a medium level of Plk1 depletion caused a 2-h delay of mitotic progression, and a high degree of Plk1 depletion significantly delayed mitotic entry and completely blocked cells at mitosis. In striking contrast, normal hTERT-RPE1 and MCF10A cells were much less sensitive to Plk1 depletion than HeLa cells; no apparent cell proliferation defect or cell cycle arrest was observed after Plk1 depletion in these cells. Therefore, these data further support suggestions that Plk1 may be a feasible cancer therapy target.
Zhang G, Pannucci A, Ivanov A, Switchenko J, Sun S, Sica G Cancers (Basel). 2025; 17(3).
PMID: 39941812 PMC: 11815996. DOI: 10.3390/cancers17030446.
Zhang Y, Fong K, Mao F, Wang R, Allison D, Napier D Cell Rep. 2024; 43(7):114431.
PMID: 38968071 PMC: 11334074. DOI: 10.1016/j.celrep.2024.114431.
PLK1 inhibition leads to mitotic arrest and triggers apoptosis in cholangiocarcinoma cells.
Moolmuang B, Chaisaingmongkol J, Singhirunnusorn P, Ruchirawat M Oncol Lett. 2024; 28(1):316.
PMID: 38807667 PMC: 11130613. DOI: 10.3892/ol.2024.14449.
Forgham H, Zhu J, Huang X, Zhang C, Biggs H, Liu L Adv Sci (Weinh). 2024; 11(25):e2401340.
PMID: 38647396 PMC: 11220643. DOI: 10.1002/advs.202401340.
Genetic enhancers of partial PLK1 inhibition reveal hypersensitivity to kinetochore perturbations.
Normandin K, Coulombe-Huntington J, St-Denis C, Bernard A, Bourouh M, Bertomeu T PLoS Genet. 2023; 19(8):e1010903.
PMID: 37639469 PMC: 10491399. DOI: 10.1371/journal.pgen.1010903.